Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 04 2021 - 7:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2021
Commission File Number 001-39446
CureVac N.V.
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM
20-F x FORM
40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:
YES ¨ NO x
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
On February 4, 2021, CureVac N.V. (the
“Company”) issued a press release announcing that the Company started an expansion of the ongoing Phase 1 study with
its lead RNA-based cancer drug candidate, CV8102.
The information in this Form 6-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
CUREVAC N.V.
|
|
|
|
|
By:
|
/s/ Franz-Werner Haas, LLD, LLM
|
|
|
Chief Executive Officer
|
Date: February 4, 2021
EXHIBIT INDEX
EXHIBIT NO.
|
|
DESCRIPTION
|
99.1
|
|
CureVac N.V. Press Release dated February 4, 2021.
|
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Apr 2024 to May 2024
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From May 2023 to May 2024